- Home
- ANVS vs MRNS Comparison
ANVS vs MRNS Comparison
Compare ANVS & MRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- MRNS
- Stock Information
- Founded
- ANVS 2008
- MRNS 2003
- Country
- ANVS United States
- MRNS United States
- Employees
- ANVS N/A
- MRNS N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- MRNS Biotechnology: Pharmaceutical Preparations
- Sector
- ANVS Health Care
- MRNS Health Care
- Exchange
- ANVS Nasdaq
- MRNS Nasdaq
- Market Cap
- ANVS 110.4M
- MRNS 104.7M
- IPO Year
- ANVS 2020
- MRNS 2014
- Fundamental
- Price
- ANVS $9.57
- MRNS $0.31
- Analyst Decision
- ANVS Strong Buy
- MRNS Buy
- Analyst Count
- ANVS 6
- MRNS 12
- Target Price
- ANVS $29.67
- MRNS $4.56
- AVG Volume (30 Days)
- ANVS 341.4K
- MRNS 5.7M
- Earning Date
- ANVS 11-06-2024
- MRNS 11-05-2024
- Dividend Yield
- ANVS N/A
- MRNS N/A
- EPS Growth
- ANVS N/A
- MRNS N/A
- EPS
- ANVS N/A
- MRNS N/A
- Revenue
- ANVS N/A
- MRNS $30,263,000.00
- Revenue This Year
- ANVS N/A
- MRNS $21.18
- Revenue Next Year
- ANVS N/A
- MRNS $56.42
- P/E Ratio
- ANVS N/A
- MRNS N/A
- Revenue Growth
- ANVS N/A
- MRNS 16.56
- 52 Week Low
- ANVS $4.53
- MRNS $0.26
- 52 Week High
- ANVS $22.49
- MRNS $11.26
- Technical
- Relative Strength Index (RSI)
- ANVS 58.70
- MRNS 21.75
- Support Level
- ANVS $9.00
- MRNS $0.29
- Resistance Level
- ANVS $10.54
- MRNS $1.96
- Average True Range (ATR)
- ANVS 0.81
- MRNS 0.12
- MACD
- ANVS 0.12
- MRNS -0.18
- Stochastic Oscillator
- ANVS 74.57
- MRNS 2.41
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
About MRNS Marinus Pharmaceuticals Inc.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.